Xiaomeng WANG   
                       
    Main Page   Staff Directory   Publications          
                       
   
a filler
  Xiaomeng WANG  
  Lab Location:
50 Nanyang Drive,
Research Techno Plaza, Level 4, X-Frontiers Block, Singapore, 637553

email:
wangxiaomeng@ntu.edu.sg
tel:65923840

 
a a a
a a a
  Key Publications  
 

Kist, R., Watson, M., Wang, X., Cairns, P., Miles, C., Reid, D.J. and Peters, H. (2005). Reduction of Pax9 gene dosage in an allelic series of mouse mutants causes hypodontia and oligodontia Hum..
Mol. Genet. 14: 3605-3617.

Wang, X., Harris, R.E., Bayston, L.J. and Ashe, H.L. (2008).
Type IV collagens regulate BMP signalling in Drosophila.
Nature 455: 72-77.

McKenzie, J.A.G., Fruttiger, M., Abraham, S., Lange, C., Stone, J., Ghandi, P., Wang, X., Bainbridge, J., Moss, S.E. and Greenwood, J. (2012).
Apelin is required for non-neovascular remodelling in the retina.
Am. J. Pathol. 180: 399-409.

Wang, X., Abrahams, S., McKenzie, J.A.G. Jeffs, N., Lange, C.A.K., Bainbridge, J., Moss, S.E. and Greenwood, J. (2013).
Lrg1 promotes angiogenesis by modulating endothelial TGFß signalling.
Nature (2013) Jul 18;499(7458):306-11

 
a a a
 
  Xiaomeng WANG

Dr Wang Xiaomeng is an Assistant Professor at the Lee Kong Chian School of Medicine, Nanyang Technological University. Prior to this appointment, Dr Wang spent her scientific career at the world-renowned University College London, UK. Dr Wang obtained her BSc. in Biology at Beijing Normal University, China and her PhD in Genetics at Newcastle University, UK. She then undertook post-doctoral training at Manchester University, UK.

Dr Wang is interested in the role of TGFβ signalling in development and under disease conditions. Her earlier work demonstrated that type IV collagen not only function as an affinity matrix for binding and immobilizing TGFβ family growth factor, Decapentaplegic (Dpp), but also regulates its signalling during Drosophila development. Her recent study led to the identification of another novel regulator of TGFβ signalling, Leucine rich alpha 2 glycoprotin 1 (Lrg1). This work revealed for the first time the function and molecular mechanism of Lrg1 regulated TGFβ signalling in pathological angiogenesis and raised the intriguing possibility of targeting Lrg1 as a novel treatment for diseases such as diabetic vascular complications, cancer, atherosclerosis and rheumatoid arthritis. Both studies have been published in Nature as an article.

Dr Wang is the co-inventor of two international patents, Treatment of vasculoproliferative conditions and Treatment of Cancer. To gain a better understanding of drug discovery, development and commercialization, Dr Wang received practical training in small molecule drug discovery from Wellcome trust advanced course and studied new technology ventures at London Business School after winning competitive bursaries.

     
  Vascular Biology Lab
 


A healthy, intact vasculature is central to normal organ and tissue function. Abnormal quantity and quality of blood vessels will cause severe complications. The focus of the Wang lab is to gain novel insights into the molecular and cellular mechanisms that modulate, inhibit and promote blood vessel formation.  The goal is to develop novel therapeutic approaches targeting angiogenesis, a key feature shared by over 70 major health conditions affecting more than one billion people worldwide. 
Research in the Wang lab is focused on the following aspects: 
1) Unravel the basic cellular principles and the molecular control of differential angiogenic responses in diabetic vascular complications.
2) Investigate the impact of LRG1 regulated TGFβ signalling in different types of diabetic vascular complications as well as in other angiogenesis-related diseases.  
3) Develop novel therapeutic approaches targeting angiogenesis for the treatment of angiogenesis-related diseases.
4) Study the role of LRG1 in TGFβ regulated fibrotic diseases.